Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
18.95 GBX | +1.07% | -7.56% | -13.86% |
Feb. 28 | Redx Pharma Doses First Patient in Early-stage Trial of Inflammatory Bowel Disease Treatment | MT |
Feb. 28 | Redx Announces That First Participant Dosed in Phase 1 Trial of RXC008 | CI |
Sales 2024 * | 13.73M 17.35M | Sales 2025 * | 1.25M 1.58M | Capitalization | 72.93M 92.15M |
---|---|---|---|---|---|
Net income 2024 * | -25M -31.59M | Net income 2025 * | -43M -54.33M | EV / Sales 2024 * | 4.77 x |
Net cash position 2024 * | 7.41M 9.36M | Net Debt 2025 * | 28.99M 36.63M | EV / Sales 2025 * | 81.4 x |
P/E ratio 2024 * |
-3.02
x | P/E ratio 2025 * |
-1.85
x | Employees | 101 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.87% |
Latest transcript on Redx Pharma Plc
1 day | +1.07% | ||
1 week | -7.56% | ||
Current month | +2.43% | ||
1 month | +2.43% | ||
3 months | -13.86% | ||
6 months | -27.12% | ||
Current year | -13.86% |
Managers | Title | Age | Since |
---|---|---|---|
Lisa Anson
CEO | Chief Executive Officer | - | 18-05-31 |
Peter J. Collum
DFI | Director of Finance/CFO | - | 21-05-04 |
Chief Operating Officer | 46 | 18-11-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Scott
BRD | Director/Board Member | 70 | 22-01-26 |
Joseph Anderson
BRD | Director/Board Member | 65 | 23-09-05 |
Peter Presland
BRD | Director/Board Member | 75 | 17-11-02 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 18.95 | +1.07% | 61 901 |
24-03-27 | 18.75 | 0.00% | 37,638 |
24-03-26 | 18.75 | -3.85% | 64,993 |
24-03-25 | 19.5 | 0.00% | 115,284 |
24-03-22 | 19.5 | -4.88% | 73,269 |
Delayed Quote London S.E., March 28, 2024 at 11:49 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.86% | 92.09M | |
+3.22% | 108B | |
+10.00% | 104B | |
+6.43% | 23.66B | |
-11.52% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-12.97% | 16.19B | |
+4.74% | 13.72B | |
+34.76% | 12.22B |